Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2002

01-05-2002 | Originales

Second-line chemotherapy with weekly paclitaxel in patients with advanced non-small-cell lung cancer

Authors: Luis Ángel León Mateos, Juan Fernando Cueva Bañuelos, María Teresa Curiel García, María Calvo Rodríguez, Begoña Graña Suárez, Sonia Candamio Folgar, Francisco Javier Barón Duarte, Rafael López López

Published in: Clinical and Translational Oncology | Issue 4/2002

Login to get access
Metadata
Title
Second-line chemotherapy with weekly paclitaxel in patients with advanced non-small-cell lung cancer
Authors
Luis Ángel León Mateos
Juan Fernando Cueva Bañuelos
María Teresa Curiel García
María Calvo Rodríguez
Begoña Graña Suárez
Sonia Candamio Folgar
Francisco Javier Barón Duarte
Rafael López López
Publication date
01-05-2002
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 4/2002
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02717674

Other articles of this Issue 4/2002

Clinical and Translational Oncology 4/2002 Go to the issue

Notas clínicas

Pancreatitis aguda inducida por L-asparraginasa

Originales Breves

Potential complications of the growing teratoma syndrome in patients with advanced germ-cell tumors: description of three cases

Revisiones

The molecular biology of topoisomerase IIα and its importance in the acquisition of multidrug resistance in cancer

Correspondencia

Cisplatin-5-fluorouracil-leucovorin (PFL) as neoadyuvant therapy in patients with locally advanced squamous cell carcinoma of the head and neck. Results after long-term follow up (réplica)

Editorial

Multidrug transporters in cancer resistance

Correspondencia

Quimioterapia en cáncer avanzado de cabeza y cuello: Aprender a pasar página
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits